Please use this identifier to cite or link to this item:
https://scholarhub.balamand.edu.lb/handle/uob/6001
Title: | Carbapenemase Inhibitors: Updates on Developments in 2021 | Authors: | Zerdan, Maroun Bou Hassan, Sally Al Shaker, Waleed Hajjar, Rayan El Allam, Sabine Zerdan, Morgan Bou Naji, Amal Zeineddine, Nabil |
Affiliations: | Faculty of Medicine | Keywords: | Carbapenem resistance Carbapenemase inhibitors Pathogens |
Issue Date: | 2022 | Part of: | Journal of Clinical Medicine Research | Volume: | 14 | Issue: | 7 | Start page: | 251 | End page: | 259 | Abstract: | Carbapenem resistance, an emerging global health problem, compromises the treatment of infections caused by nosocomial pathogens. Preclinical and clinical trials demonstrate that a new generation of carbapenemases inhibitors, together with the recently approved avi-bactam, relebactam and vaborbactam, would address this resistance. Our review summarizes the latest developments related to carbap-enemase inhibitors synthesized to date, as well as their spectrum of activity and their current stage of development. A particular focus will be on β-lactam/β-lactamase inhibitor combinations that could potentially be used to treat infections caused by carbapenemase-producer pathogens. These new combinations mark a critical step forward the fight against antimicrobial resistance. |
URI: | https://scholarhub.balamand.edu.lb/handle/uob/6001 | ISSN: | 19183003 | DOI: | 10.14740/jocmr4764 | Open URL: | Link to full text | Type: | Journal Article |
Appears in Collections: | Faculty of Medicine |
Show full item record
Record view(s)
9
checked on Feb 6, 2023
Google ScholarTM
Check
Dimensions Altmetric
Dimensions Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.